^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung cancer Un ensayo clínico para comparar la eficacia de savolitinib más osimertinib frente a la quimioterapia para el tratamiento del cáncer de pulmón no microcítico
Excerpt:
...Se permiten todos los sexos.- CPNM localmente avanzado o metastásico confirmado histológica o citológicamente que no sea susceptible de tratamiento curativo.- Debe tener al menos una mutación sensibilizante del EGFR documentada: deleción del exón 19, mutación L858R y/o T790M.- Progresión radiológica documentada en el tratamiento de primera o segunda línea con osimertinib como tratamiento antineoplásico más reciente.- Suministro obligatorio de tejido tumoral FFIP.- Tener sobreexpresión y/o amplificación de MET en la muestra tumoral obtenida después de la progresión con el tratamiento previo con osimertinib.- Enfermedad medible según la definición de RECIST 1.1. ...
Trial ID:
Source:
Title:
Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
Excerpt:
...MET amplification/high expression as determined by FISH, IHC or NGS testing on tumor tissue collected before any systemic treatment in first line....
Trial ID:
More C2 evidence
Source:
Title:
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
Excerpt:
...- Have MET amplification as determined by central MET FISH testing on tumour specimen collected following progression on prior osimertinib treatment....
Trial ID:
Source:
Title:
Osimertinib plus savolitinib in patients with EGFRm+/MET+ non small cell lung cancer following prior osimertinib
Excerpt:
...All genders are permitted.- Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is not amenable to curative therapy.- Documented radiologic disease progression on first line osimertinib.- MET-amplification and/or overexpression (FISH10+ and/or IHC90+) as determined by FISH (central) and IHC (central) testing on tumour sample collected following progression on 1L osimertinib treatment.- Available tumour sample for central MET FISH and IHC analysis or willingness to collect additional tissue for central testing which fulfils the following requirements: Obtained following progression on previous osimertinib therapy; obtained within 2 years of submission for MET analysis; sufficient tissue to meet the minimum tissue requirement defined in the current Laboratory Manual. ...
Trial ID:
Source:
Title:
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Excerpt:
...- MET amplification and/or overexpression (FISH10+ and/or IHC90+) as determined by FISH (central) and IHC (central) testing on tumour sample collected following progression on 1L osimertinib treatment....
Trial ID:
Less C2 evidence
Source:
Title:
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Published date:
11/27/2023
Excerpt:
Median TTF of 1L savo mono in pts with MET ex14m was 12.6months and median TTF of savo plus osi in pts with resistant MET amp was 11.3 months….The real-world analysis results showed the promising clinical benefit of savo in NSCLC pts with MET alterations and the acceptable safety.
Source:
Title:
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Excerpt:
Here, we present a case of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET, who after progression on erlotinib responded dramatically to combined MET and EGFR inhibition with savolitinib and osimertinib.
DOI:
10.1158/2159-8290.CD-16-0686
Source:
Title:
Abstract 3017: Using a pharmacodynamic biomarker led approach to explore and quantify the combination effect of savolitinib and osimertinib in the LG1208 NSCLC PDX model
Published date:
05/15/2020
Excerpt:
Combination efficacy of savolitinib and osimertinib was tested in an EGFRm (L858R) and MET-amplified LG1208 PDX model, resistant to osimertinib...Upon combination, at a fixed dose of osimertinib (10 mg/kg), anti-tumor activity increased with savolitinib dose, ranging from 1 mg/kg (99.8 % TGI) to 15 mg/kg (77.9% regression).
DOI:
10.1158/1538-7445.AM2020-3017
